GlassScriptPhysician profile
Michelle Elizabeth Wright Mast
NPI 1538353073
$6,991.54
in general payments reported to CMS, 2019-2025
42 companies · $816 in 2025
The $816 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.93 · 2022: $1,272 · 2023: $1,651 · 2024: $3,158 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797 · Long Term Medical Supply Or Device Loan: $1,080 · Education: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,797.39 |
| Long Term Medical Supply Or Device Loan | $1,080.33 |
| Education | $746.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,850.81 | 2022-2025 | |
| Astellas Pharma US INC | $548.79 | 2022-2025 | Xospata, Xtandi, Vyloy |
| Seagen INC. | $546.20 | 2022-2023 | Tukysa |
| Genzyme Corporation | $348.11 | 2021-2025 | |
| Pfizer INC. | $269.01 | 2023-2025 | |
| Janssen Biotech, INC. | $256.45 | 2022-2024 | Tecvayli, Darzalex, Imbruvica |
| Abbvie INC. | $250.74 | 2022-2025 | |
| Daiichi Sankyo INC. | $235.17 | 2021-2025 | Enhertu, Injectafer |
| Gilead Sciences, INC. | $206.36 | 2023-2025 | Trodelvy |
| Incyte Corporation | $193.48 | 2024-2025 | Jakafi, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $178.01 | 2021-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $160.11 | 2023-2025 | Lynparza |
| Amgen INC. | $147.24 | 2022-2023 | Lumakras, Kyprolis |
| Sobi, INC | $146.88 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $145.59 | 2024-2025 | Opdivo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $134.25 | 2023-2024 | Cabometyx |
| Lilly USA, LLC | $125.13 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Stemline Therapeutics INC. | $121.18 | 2023 | Orserdu |
| Celgene Corporation | $120.59 | 2022-2025 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $94.31 | 2022 | |
| Alexion Pharmaceuticals, INC. | $92.37 | 2023-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $87.38 | 2024-2025 | Keytruda, Welireg |
| Pharmacosmos Therapeutics INC. | $82.89 | 2022-2024 | Monoferric |
| Eisai INC. | $75.96 | 2023-2024 | |
| Acrotech Biopharma INC. | $75.27 | 2023-2024 | Beleodaq |
| Genentech USA, INC. | $59.09 | 2022-2023 | Gavreto, Alecensa, Rozlytrek |
| Tersera Therapeutics LLC | $55.51 | 2023-2024 | Zoladex |
| Array Biopharma INC | $43.62 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Adaptive Biotechnologies Corporation | $42.65 | 2024-2025 | Clonoseq |
| Genmab U.S., INC. | $39.61 | 2023-2025 | Tivdak, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.30 | 2023 | Iclusig |
| Geron Corporation | $24.82 | 2025 | Rytelo |
| Coherus Oncology, INC. | $24.21 | 2024 | |
| Cti Biopharma Corp. | $23.39 | 2023 | Vonjo |
| Regeneron Healthcare Solutions, INC. | $19.51 | 2024 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $19.01 | 2023 | Tazverik |
| Pharmaessentia USA Corporation | $18.27 | 2022 | |
| Beigene USA, INC. | $17.70 | 2023 | Brukinsa |
| Foundation Medicine, INC. | $17.15 | 2023 | |
| Travere Therapeutics, INC. | $16.13 | 2024 | |
| Taiho Oncology, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Wright Mast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.